OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
OncoSec Medical (NASDAQ: ONCS) announced that Interim CEO Brian Leuthner and Chief Clinical Development Officer Sandra Aung will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9-10, 2021. The chat will take place at 2:00 PM ET on August 9. A replay will be available on the conference website for BTIG clients. OncoSec focuses on cytokine-based immunotherapies, with their lead candidate TAVO™ targeting various cancers. Recent studies show promising immune responses, justifying further development of their innovative treatments.
- None.
- None.
PENNINGTON, N.J. and SAN DIEGO, July 26, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Interim CEO and Chief Operating Officer, Brian Leuthner, and Senior Vice President, Chief Clinical Development Officer, Sandra Aung, Ph.D., will participate in a fireside chat at the BTIG Virtual Biotechnology Conference being held Monday, August, 9th – Tuesday, August 10th, 2021.
BTIG Virtual Biotechnology Conference
Date: Monday, August 9th
Time: 2:00pm ET
For those not attending, a replay of the presentation will be available until the end of the conference on the BTIG conference website. Must be a BTIG client to attend and access the replay.
About OncoSec Medical Incorporated
OncoSec Medical Incorporated (the "Company," "OncoSec," "we" or "our") is a biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy investigational product candidate – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach along with an acceptable safety profile, warranting further development. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visit www.oncosec.com.
TAVO™ is a trademark of OncoSec Medical Incorporated.
Company Contact
Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Media Contact
Patrick Bursey
LifeSci Communications
+1-646-970-4688
pbursey@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncosec-to-participate-in-fireside-chat-at-btig-virtual-biotechnology-conference-301340818.html
SOURCE OncoSec Medical Incorporated
FAQ
When is the BTIG Virtual Biotechnology Conference for OncoSec Medical?
Who will represent OncoSec Medical at the BTIG Virtual Biotechnology Conference?
What is OncoSec Medical's lead immunotherapy product?
What recent results have been reported for TAVO™ by OncoSec Medical?
How can I access the replay of OncoSec's presentation at the BTIG conference?
